about
Vaccine protection against Zika virus from BrazilZika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus MonkeysLongitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsVaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infectionImmediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses.Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice.Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys.Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection.Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys.Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors.Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challengeCombined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and EfficacyPotent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donorNS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice
P50
Q25165129-67EC45D0-BA5E-4737-AA3D-C5A58F724E51Q29587262-2CE37EBE-4660-49B9-AED5-688A0B1BB71AQ33630150-EF47DCBB-C606-4C4B-B4F6-FC61C857A3E4Q34057708-6B0B0E67-15DB-48B5-AB0C-29F584BE2B9BQ35241486-C642528B-4AF2-4D5E-AA2B-E939403B89E3Q37189696-3E3703DE-FA5A-48DE-8859-CC3C3E52E655Q37287424-AC84840C-4E36-4669-9B3B-806D5420F630Q37661779-74E979FB-D54F-48EF-A1AE-CB203796B000Q40005891-C95A2172-5885-40B3-91A1-FBA08A22E7A5Q45323630-BDDFB421-C331-4172-AA6E-832118434386Q47555891-C98A5FA4-9C7A-46F5-8378-F21F80BE4BA6Q47558367-47CBA6C8-D575-46CB-94EA-D470104D7D19Q51335899-5FBF713A-34C1-4B79-BC64-ECEEB54FE300Q52668670-999F3B36-8A96-4360-8D47-D491FD20D759Q53699647-71F65B7D-538E-4568-86DB-0B4ED902B47AQ55084408-188D4250-62F9-4592-8606-A1F1BC0FB840Q55387941-D0F03A90-BC5D-46E9-B310-49D99D01B79CQ56337689-FA162D42-C779-4C1B-BBAC-29A9D0C920DDQ58699767-BE5517B9-42DA-4511-9C27-7382BEF61F79Q89519312-BAB2F0D6-CBF9-4DE1-984A-EDEE9FE3E19FQ92028890-0DEDD9C2-3A85-44DE-8DF1-32810016B983
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rafael A Larocca
@ast
Rafael A Larocca
@en
Rafael A Larocca
@es
Rafael A Larocca
@nl
Rafael A Larocca
@sl
type
label
Rafael A Larocca
@ast
Rafael A Larocca
@en
Rafael A Larocca
@es
Rafael A Larocca
@nl
Rafael A Larocca
@sl
prefLabel
Rafael A Larocca
@ast
Rafael A Larocca
@en
Rafael A Larocca
@es
Rafael A Larocca
@nl
Rafael A Larocca
@sl
P1053
H-1655-2015
P106
P21
P31
P3829
P496
0000-0002-9995-1804